Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Mario Sznol
98  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

Table_4_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s006.  , 2024
Link: https://doi.org/10.3389/..
 
?
2

Table_3_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
https://figshare.com/articles/dataset/Table_3_Immunotherapy_utilization_in_stage_IIIA_melanoma_less_may_be_more_docx/25149845.  , 2024
Link: https://doi.org/10.3389/..
 
?
3

Trial Protocol 1 from A Phase II Trial of the CD40 Agonisti..:

Sarah A. Weiss ; Mario Sznol ; Montaser Shaheen...
doi:10.1158/1078-0432.24947878.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
4

Presentation_1_Immunotherapy utilization in stage IIIA mela..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s001.  , 2024
Link: https://doi.org/10.3389/..
 
?
5

Table_4_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s006.  , 2024
Link: https://doi.org/10.3389/..
 
?
6

Table_2_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
https://figshare.com/articles/dataset/Table_2_Immunotherapy_utilization_in_stage_IIIA_melanoma_less_may_be_more_docx/25149836.  , 2024
Link: https://doi.org/10.3389/..
 
?
7

Presentation_2_Immunotherapy utilization in stage IIIA mela..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
https://figshare.com/articles/presentation/Presentation_2_Immunotherapy_utilization_in_stage_IIIA_melanoma_less_may_be_more_pptx/25149827.  , 2024
Link: https://doi.org/10.3389/..
 
?
8

Table_6_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
https://figshare.com/articles/dataset/Table_6_Immunotherapy_utilization_in_stage_IIIA_melanoma_less_may_be_more_docx/25149863.  , 2024
Link: https://doi.org/10.3389/..
 
?
9

Table_1_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s003.  , 2024
Link: https://doi.org/10.3389/..
 
?
10

Presentation_2_Immunotherapy utilization in stage IIIA mela..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s002.  , 2024
Link: https://doi.org/10.3389/..
 
?
11

Table_3_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s005.  , 2024
Link: https://doi.org/10.3389/..
 
?
12

Table_6_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s008.  , 2024
Link: https://doi.org/10.3389/..
 
?
13

Table_3_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s005.  , 2024
Link: https://doi.org/10.3389/..
 
?
14

Table_1_Immunotherapy utilization in stage IIIA melanoma: l..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
doi:10.3389/fonc.2024.1336441.s003.  , 2024
Link: https://doi.org/10.3389/..
 
?
15

Presentation_1_Immunotherapy utilization in stage IIIA mela..:

Alexander E. Frey ; Daniel M. Kerekes ; Sajid A. Khan...
https://figshare.com/articles/presentation/Presentation_1_Immunotherapy_utilization_in_stage_IIIA_melanoma_less_may_be_more_pptx/25149824.  , 2024
Link: https://doi.org/10.3389/..
 
1-15